TXMD Fundamental Analysis - THERAPEUTICSMD INC

Name: THERAPEUTICSMD INC (TXMD) Stock
Brand: THERAPEUTICSMD INC
Rating: 5 (3 reviews)

Fundamental Rating

TXMD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. TXMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TXMD is valued correctly, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TXMD has reported negative net income.

TXMD had a positive operating cash flow in the past year.

TXMD had negative earnings in 4 of the past 5 years.

TXMD had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

TXMD has a Return On Assets of -1.19%. This is in the better half of the industry: TXMD outperforms 77.60% of its industry peers.

Looking at the Return On Equity, with a value of -1.68%, TXMD belongs to the top of the industry, outperforming 80.21% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-1.19%
ROE	-1.68%
ROIC	N/A

ROA(3y)31.47%

ROA(5y)-21.67%

ROE(3y)92.01%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TXMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for TXMD remains at a similar level compared to 1 year ago.

Compared to 5 years ago, TXMD has more shares outstanding

TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -33.70, we must say that TXMD is in the distress zone and has some risk of bankruptcy.

TXMD has a Altman-Z score of -33.70. This is amonst the worse of the industry: TXMD underperforms 86.98% of its industry peers.

TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	-33.7

ROIC/WACCN/A

WACC8.75%

2.3 Liquidity

TXMD has a Current Ratio of 2.89. This indicates that TXMD is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 2.89, TXMD is in line with its industry, outperforming 56.25% of the companies in the same industry.

A Quick Ratio of 2.89 indicates that TXMD has no problem at all paying its short term obligations.

TXMD has a Quick ratio (2.89) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.89
Quick Ratio	2.89

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TXMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.26%, which is quite impressive.

TXMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 156.16%.

The Revenue for TXMD have been decreasing by -48.72% on average. This is quite bad

EPS 1Y (TTM)91.26%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%151.7%

Revenue 1Y (TTM)156.16%

Revenue growth 3Y-11.84%

Revenue growth 5Y-48.72%

Sales Q2Q%306.84%

3.2 Future

Based on estimates for the next years, TXMD will show a decrease in Earnings Per Share. The EPS will decrease by -8.87% on average per year.

The Revenue is expected to grow by 1.92% on average over the next years.

EPS Next Y0%

EPS Next 2Y-30.31%

EPS Next 3Y-18.42%

EPS Next 5Y-8.87%

Revenue Next Year1.11%

Revenue Next 2Y1.65%

Revenue Next 3Y1.82%

Revenue Next 5Y1.92%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TXMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

With a Price/Forward Earnings ratio of 7.44, the valuation of TXMD can be described as very cheap.

TXMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. TXMD is cheaper than 89.58% of the companies in the same industry.

TXMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.99, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	7.44

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of TXMD indicates a rather cheap valuation: TXMD is cheaper than 84.90% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	17.83
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as TXMD's earnings are expected to decrease with -18.42% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-30.31%

EPS Next 3Y-18.42%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TXMD!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

THERAPEUTICSMD INC

NASDAQ:TXMD (10/24/2025, 8:00:02 PM)

After market: 1.27 -0.02 (-1.55%)

1.29

-0.02 (-1.53%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-11 2025-08-11

Earnings (Next)11-10 2025-11-10

Inst Owners28.19%

Inst Owner Change0%

Ins Owners1.55%

Ins Owner Change0%

Market Cap14.93M

Revenue(TTM)2.56M

Net Income(TTM)-459000

Analysts43.33

Price TargetN/A

Short Float %0.34%

Short Ratio0.19

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	7.44
P/S	5.83
P/FCF	17.83
P/OCF	17.83
P/B	0.55
P/tB	0.64
EV/EBITDA	N/A

EPS(TTM)-0.05

EYN/A

EPS(NY)0.17

Fwd EY13.44%

FCF(TTM)0.07

FCFY5.61%

OCF(TTM)0.07

OCFY5.61%

SpS0.22

BVpS2.36

TBVpS2.01

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.19%
ROE	-1.68%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	32.71%

ROA(3y)31.47%

ROA(5y)-21.67%

ROE(3y)92.01%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score7

Asset Turnover0.07

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.89
Quick Ratio	2.89
Altman-Z	-33.7

F-Score7

WACC8.75%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)91.26%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%151.7%

EPS Next Y0%

EPS Next 2Y-30.31%

EPS Next 3Y-18.42%

EPS Next 5Y-8.87%

Revenue 1Y (TTM)156.16%

Revenue growth 3Y-11.84%

Revenue growth 5Y-48.72%

Sales Q2Q%306.84%

Revenue Next Year1.11%

Revenue Next 2Y1.65%

Revenue Next 3Y1.82%

Revenue Next 5Y1.92%

EBIT growth 1Y53.54%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y100.65%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y100.65%

OCF growth 3YN/A

OCF growth 5YN/A

THERAPEUTICSMD INC / TXMD FAQ

What is the ChartMill fundamental rating of THERAPEUTICSMD INC (TXMD) stock?

ChartMill assigns a fundamental rating of 4 / 10 to TXMD.

What is the valuation status for TXMD stock?

ChartMill assigns a valuation rating of 4 / 10 to THERAPEUTICSMD INC (TXMD). This can be considered as Fairly Valued.

What is the profitability of TXMD stock?

THERAPEUTICSMD INC (TXMD) has a profitability rating of 2 / 10.

What is the earnings growth outlook for THERAPEUTICSMD INC?

The Earnings per Share (EPS) of THERAPEUTICSMD INC (TXMD) is expected to decline by 0% in the next year.

THERAPEUTICSMD INC (TXMD) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

THERAPEUTICSMD INC / TXMD FAQ

What is the ChartMill fundamental rating of THERAPEUTICSMD INC (TXMD) stock?

What is the valuation status for TXMD stock?

What is the profitability of TXMD stock?

What is the earnings growth outlook for THERAPEUTICSMD INC?